CRISPR Therapeutics (CRSP) Expected to Announce Quarterly Earnings on Wednesday
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) will likely be announcing its earnings results before the market opens on Wednesday, February 19th. Analysts expect the company to announce earnings of ($1.
Why CRISPR Therapeutics (CRSP) Soared on Friday?
We recently published a list of Shares of 10 Firms Soar on Friday. In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against other firms that soared on Friday.
CRISPR Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy?
CRISPR Therapeutics CRSP is expected to report fourth-quarter and full-year 2024 earnings later this month. The Zacks Consensus Estimate for quarterly sales is pegged at $10.13 million, while that for earnings is pinned at a loss of $1.
Crispr Therapeutics: Why I've Become Even More Bullish (Rating Upgrade)
Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising partnerships. Click for my CRSP stock update.
CRISPR Therapeutics Stock Upgrade Following Analyst Reassessment
CRISPR Therapeutics (CRSP, Financials) stock rose 16.4% to $50.60 as of 10:10 a.m. GMT-5 on Friday, following an analyst upgrade. Citing pipeline advancements and possible catalysts, Evercore ISI analyst Liisa Bayko raised CRISpen Therapeutics from "In Line" to "Outperform.
Crispr Therapeutics upgraded to Outperform from In Line at Evercore ISI
Evercore ISI analyst Liisa Bayko upgraded Crispr Therapeutics (CRSP) to Outperform from In Line with a price target of $99, up from $60.
CRISPR upped to outperform by Evercore on upcoming data
Evercore ISI has upgraded CRISPR Therapeutics (NASDAQ:CRSP) to outperform from in line, citing upcoming catalysts. The investment firm said it was now including the CTX320 and CTX310 in vivo programs in its price target,
Crispr Therapeutics price target lowered to $82 from $89 at Citi
Citi analyst Yigal Nochomovitz lowered the firm’s price target on Crispr Therapeutics (CRSP) to $82 from $89 and keeps a Buy rating on the ...
The Goldman Sachs Group Cuts CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $57.00
CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its price objective cut by The Goldman Sachs Group from $66.00 to $57.00 ...
Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future
Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...
Q4 Earnings Surprise Greenlights CRISPR Therapeutics Stock Climb
CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The ...
CRISPR Therapeutics Q4 Earnings and Revenues Surpass Estimates
CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is ...
STAT12d
The CRISPR companies are not OK
Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR ...
Xinhua2d
Bahrain conducts 1st CRISPR-based sickle cell treatment outside U.S.
MANAMA, Feb. 16 (Xinhua) -- Bahrain has achieved a medical milestone by successfully treating a patient with sickle cell disease (SCD) using CRISPR-based gene-editing therapy, Casgevy, the Bahrain ...
CRISPR’s cardio catch-all drives a biotech’s broad potential
Scribe Therapeutics hopes to prevent cardiometabolic diseases by targeting underlying causes with CRISPR technology.